web analytics
14.6 C
Munich
Sunday, September 25, 2022

Remarkable Rise of Instant Test GenViro(TM) & Decision Diagnostics Corp (OTCMKTS: DECN)

Decision Diagnostics Corp (OTCMKTS: DECN) is an exciting story in small caps that has been gaining traction as the Company markets its GenViro(TM) Corona Virus Screening Kit; a timely, simple to use, cost effective instant test that provides results in as little as 10.5 seconds, based on a small finger prick blood sample. The device costs $15 and the test strip kit costs $30.

As Countries prepare to reopen they depend on the ability for rapid testing – widespread, affordable, accurate and accessible testing. Antibody tests and nasal swabs currently on the market are both invasive and take up to weeks for results. DECN many have the solution with its GenViro(TM) Corona Virus Screening Kit; a product that works fast and is affordable.

Decision Diagnostics Corp (OTCMKTS: DECN) is a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With newly inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company’s new GenViro!™ product designed to test for Covid-19, is not yet available in the United States or Puerto Rico, but Emergency (EUA) Waivers are in process with the U.S. FDA. Decision Diagnostics has submitted two applications with the FDA for a Covid-19 testing technology that identify the virus in ten (10) seconds or less. The company has been in discussions with the FDA on final testing protocols since mid-April.)

Decision Diagnostics introduced its GenViro(TM) Corona Virus Screening Kit in March. The Company stated at the time: Today, in the third discussion of our break-through test for the coronavirus (COVID19), we present the Coronavirus test kit and the Phase 1 unit forecast. The introduction of our new screening methodology for the Coronavirus (Covid19) will provide a timely, simple to use and cost effective solution for the screening of the frightening COVID19 virus. First uses of our kits will be in pharmacies, doctor’s offices, clinics and urgent care centers, and long term care facilities. We anticipate the sale of 420,000,000 kits in the first full year of commercial sale. The company has retained FDA counsel who is in the process of securing expected emergency waiver for diagnostics and diagnostic devices.

GenViro(TM) Corona Virus Screening Kit has been getting picked up by main stream media with CBS New York coverfing it in a segment called: Max Minute: Diabetes Company’s Affordable, Fast Coronavirus Test May Be Key To Reopening Businesses. According to the segment: NEW YORK (CBSNewYork) – “We’re the product of choice because it works, it works fast and because it’s affordable,” According to DECN CEO Keith Berman says of the GenViro(TM) Corona Virus Screening Kit “It works by taking a finger-prick drop of blood and, through sophisticated micro-processing, arrives at a result within 30 to 45 seconds. The device costs $15 and the test strip kit costs $30. That’s why companies are interested. Businesses can test their workers as often as they want, in a matter of seconds, everyday if they like,” said Berman. The segment ends with “It’s not free, but it is an affordable enough technology that could open up restaurants, movies, all manner of businesses and group venues. The company hopes to have all the FDA-mandated testing done by next week. If approved, Berman says they could ship as many as 100,000 units immediately and be making up to 400,000 a week within 60 days.”

To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DECNDECN is currently preparing for U.S. based testing of its COVID-19 test kits. The company just received completed testing from its Korean partner where the required 75 non-infected donors were tested for both blood and saliva (a total of 150). DECN expects to receive the U.S. supply of production testing samples during the first week of August 2020 which is expected to coincide with the company’s selection of an experienced US based clinical testing partner. The company has narrowed potential US testing partners to two clinical trials organizations and allied laboratories and expects to announce its decision in the next few days. That organization will lead the clinical trials in the U.S. that DECN expects will be the final requirement to secure FDA emergency authorization.

DECN CEO recently released an open letter on FDA At-Home COVID-19 Rapid Testing Guidelines Saying It’s the Speed to Results Reporting and Certain Added Regulations That Need to Be Addressed. Mr Kieth Berman stated: “We hear every day about new “rapid” tests, both in the press and from government officials, so I ask what is meant by the term “rapid,” and moreover, how does a manufacturer or distributor deal with the new FDA at-home reporting requisites which counter the most long-awaited benefits of an at-home test – its anonymity”

According to DECN CEO Keith Berman, “While the actual testing requirements can be debated in terms of being too stringent and needing realignment, the fact is that we need to clearly define the meaning of “rapid” when we refer to Covid-19 testing, and then address the “hidden” regulatory requirements that could significantly slow and inhibit such testing. The current reporting required by the FDA guidelines and red tape requirements are a serious impediment and present significant sticking points to getting a truly rapid at-home point-of-care test in the public’s hands anytime soon.”

We have a Monster Pick Coming. Subscribe Right Now!

DECN is an exciting story in small caps that has seen 3 explosive pops over $0.40 in the past 3 months alone! DECN GenViro(TM) Corona Virus Screening Kit provides results in as little as 10.5 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19.  DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company’s new GenViro!™ product designed to test for Covid-19, is not yet available in the United States or Puerto Rico, but Emergency (EUA) Waivers are in process with the U.S. FDA. Decision Diagnostics has submitted two applications with the FDA for a Covid-19 testing technology that identify the virus in ten (10) seconds or less. The company has been in discussions with the FDA on final testing protocols since mid-April.) We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.

More articles

3 COMMENTS

  1. “OTC Markets Group Inc. (“OTC Markets”) has discontinued the display of quotes on http://www.otcmarkets.com for this security because it has been labeled Caveat Emptor (Buyer Beware). OTC Markets Group designates certain securities as “Caveat Emptor” and places a skull and crossbones icon next to the stock symbol to inform investors that there may be reason to exercise additional caution and perform thorough due diligence before making an investment decision in that security.”

  2. Thank you Bobby. We posted the skull & crossbones designation from OtcMarkets Group in prior articles on DECN and got a lot of negative feedback from ppl so we stopped inluding it. The fact that DECN is Caveet Emptor is important information to know. More experienced penny stock speculators generally stay away from skull & crossbones as you can wake up one morning and your entire investment no longer exists.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.